As with similar to China's medical insurance system, it has important reference value to take Japan, South Korea and Taiwan, China as the research object. By learning from the specific practices such as the management of medical insurance access, the formulation of payment standards and the continuation of indication rules for multi-indication drugs in these areas, it proposes to actively explore the pricing model of comparative cost and reward premium, explore the establishment and application of RSA(Risk-Sharing Agreement) mechanism, and strengthen the construction of health technology evaluation team in medical insurance institutions.